Davies M, Mawer E B, Adams P H
J Clin Endocrinol Metab. 1977 Aug;45(2):199-208. doi: 10.1210/jcem-45-2-199.
The metabolism of isotopically-labelled cholecalciferol and the response to small doses of 1,25-dihydroxycholecalciferol (1,25-(OH)2D3) was studied in a group of women with osteoporosis presenting with crush vertebral fracture. No abnormality of vitamin D metabolism was detected. The administration of 1 microgram 1,25-(OH)2D3 for between 8 and 20 days was associated with an increased intestinal absorption and urinary excretion of calcium but caused no improvement in calcium balance. There was a small but significant rise in serum calcium and phosphorus and significant reduction in immunoassayable parathyroid hormone levels during treatment. It is concluded that 1,25-(OH)2D3 is unlikely to be of value in the management of osteoporosis.
对一组因椎体压缩性骨折而患有骨质疏松症的女性进行了同位素标记胆钙化醇的代谢及对小剂量1,25 - 二羟胆钙化醇(1,25-(OH)₂D₃)反应的研究。未检测到维生素D代谢异常。给予1微克1,25-(OH)₂D₃,持续8至20天,会使肠道钙吸收增加和尿钙排泄增多,但并未改善钙平衡。治疗期间血清钙和磷有小幅但显著升高,免疫分析可测甲状旁腺激素水平显著降低。结论是1,25-(OH)₂D₃在骨质疏松症治疗中不太可能有价值。